Product
MT-3921
Aliases
Unasnemab
4 clinical trials
3 indications
Indication
HTLV-1-Associated Myelopathy (HAM)Indication
Spinal Cord InjuryIndication
Healthy Adult MalesClinical trial
A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)Status: Completed, Estimated PCD: 2023-09-14
Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Study to Investigate the Safety, Tolerability , Pharmacokinetics of Single Ascending Dose of MT-3921 in Subjects With Acute Spinal Cord InjuryStatus: Completed, Estimated PCD: 2021-01-06
Clinical trial
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesStatus: Completed, Estimated PCD: 2022-12-24